Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Llovet, J.
Ricci, S.
Mazzaferro, V.
Hilgard, P.
Raoul, J.
Zeuzem, S.
Poulin-Costello, M.
Moscovici, M.
Voliotis, D.
Bruix, J.
机构：
[1] Mt Sinai Sch Med, New York, NY USA
[2] St Chiara Univ Hosp, Pisa, Italy
[3] Natl Canc Inst, Milan, Italy
[4] Univ Hosp Essen, Essen, Germany
[5] Ctr Eugene Marquis, Rennes, France
[6] JW Goethe Univ Hosp, Frankfurt, Germany
[7] Bayer HealthCare, Toronto, ON, Canada
[8] Bayer SpA PH, Milan, Italy
[9] Bayer HealthCare, Wuppertal, Germany
[10] Hosp Clin Barcelona, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
    Kwok, Gin Wai
    Tang, Vikki
    Leung, Roland Ching-Yu
    Lee, Ann-Shing
    Law, Ada
    Chiu, Joanne Wing Yan
    Li, Bryan
    Cheung, Tan To
    Yau, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [24] Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
    Yau, Thomas Cheung
    Tang, Vikki
    Leung, Roland Ching-Yu
    Kwok, Gin Wai
    Lee, Ann-Shing
    Law, Ada
    Chiu, Joanne
    Li, Bryan
    Cheung, Tan To
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Chen, Yen-Hsun
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Chan, S. L.
    Miksad, R.
    Cicin, I.
    Chen, Y.
    Klumpen, H. J.
    Kim, S.
    Lin, Z. Z.
    Youkstetter, J.
    Sen, S.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] A RANDOMIZED, CONTROLLED PHASE III TRIAL OF SORAFENIB WITH OR WITHOUT CONVENTIONAL TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (STAH)
    Park, J. -W.
    Kim, Y. J.
    Kim, D. Y.
    Bae, S. H.
    Yeon, J. E.
    Han, S. Y.
    Hwang, J. S.
    Lee, Y. -J.
    Cheong, J. Y.
    Kwon, O. S.
    Kim, H. Y.
    Lee, H. C.
    Heo, J.
    Kim, B. H.
    Paik, S. W.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S857 - S857
  • [28] Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial
    Cheng, Ann-Lii
    Finn, Richard S.
    Kudo, Masatoshi
    Llovet, Josep M.
    Qin, Shukui
    Le Berre, Marie-Aude
    Krissel, Heiko
    Bruix, Jordi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
    Palmer, Daniel H.
    Peck-Radosavljevic, Markus
    Ma, Yuk Ting
    Graham, Janet
    Fartoux, Laetitia
    Hubner, Richard
    Loembe, Arsene Bienvenu
    Studeny, Matus
    Hocke, Julia
    Meyer, Tim
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.
    Ikeda, Masafumi
    Shimizu, Satoshi
    Sato, Tosiya
    Morimoto, Manabu
    Inaba, Yoshitaka
    Kojima, Yasushi
    Hagihara, Atsushi
    Kudo, Masatoshi
    Nakamori, Shoji
    Kaneko, Shuichi
    Sugimoto, Rie
    Tahara, Toshiyuki
    Ohmura, Takumi
    Yasui, Kohichiroh
    Sato, Keiko
    Ishii, Hiroshi
    Furuse, Junji
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345